Bionomics Starts Phase I Cancer Trial
Australia based Bionomics has reported the initiation of treatment for the first patient in the Phase I trial of its anticancer drug, BNC105
The primary objective for this trial is the evaluation of the safety and tolerability of BNC105. The results obtained from this trial will enable the identification of an appropriate dose of BNC105 for subsequent trials. Further objectives include the evaluation of BNC105 pharmacokinetics and its activity against tumour vasculature and tumour growth.
The trial involves treatment of patients with advanced cancer. Patients will be treated with BNC105 on days one and eight of a 21 day cycle, over two cycles. The trial will be conducted at clinical sites within the Cancer Trials Australia network at the Royal Melbourne Hospital, the Peter MaCallum Cancer Centre and the Western Hospital in Melbourne.